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Abstract
Background: The Mini-Mental State Examination (MMSE) has contributed to detecting cognitive
impairment, yet few studies have evaluated its accuracy when used by general practitioners (GP) in
an actual public-health setting.
Objectives: We evaluated the accuracy of MMSE scores obtained by GPs by comparing them to
scores obtained by Alzheimer's Evaluation Units (UVA).
Methods: The study was observational in design and involved 59 voluntary GPs who, after having
undergone training, administered the MMSE to patients with symptoms of cognitive disturbances.
Individuals who scored ≤ 24 (adjusted by age and educational level) were referred to Alzheimer's
Evaluation Units (UVA) for diagnosis (including the MMSE). UVAs were unblinded to the MMSE
score of the GP. To measure interrater agreement, the weighted Kappa statistic was calculated. To
evaluate factors associated with the magnitude of the difference between paired scores, a linear
regression model was applied. To quantify the accuracy in discriminating no cognitive impairment
from any cognitive impairment and from Alzheimer's disease (AD), the ROC curves (AUC) were
calculated.
Results: For the 317 patients, the mean score obtained by GPs was significantly lower (15.8 vs.
17.4 for the UVAs; p < 0.01). However, overall concordance was good (Kappa = 0.86). Only the
diagnosis made by the UVA was associated with the difference between paired scores: the adjusted
mean difference was 3.1 for no cognitive impairment and 3.8 for mild cognitive impairment. The
AUC of the scores for GPs was 0.80 (95%CI: 0.75–0.86) for discriminating between no impairment
and any impairment and 0.89 (95%CI: 0.84–0.94) for distinguishing patients with AD, though the
UVA scores discriminated better.
Conclusion: In a public-health setting involving patients with symptoms of cognitive disturbances,
the MMSE used by the GPs was sufficiently accurate to detect patients with cognitive impairment,
particularly those with dementia.
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Background
In industrialized countries, dementia is one of the main
causes of death and disability for persons over 65 years of
age. Dementing illnesses also have a strong impact on the
quality of life of both patients and their families [1],
requiring a complex organization of social and health
services.
In Italy, among persons aged 65–84 years, the prevalence
of any form of dementia has been estimated to be around
6%, whereas the estimated prevalence of Alzheimer's dis-
ease (AD) is around 2.5% [2]. When also considering per-
sons older than 84 years, the estimated prevalence ranges
from 5.9% to 6.4% for any dementia and from 3% to
3.3% for AD [3,4].
The initial stage of dementia is frequently not identified as
such, with diagnosis often being performed two or three
years after the first symptoms [5]. At present, it is not rec-
ommended that screening for non-symptomatic persons
be performed, given the high rate of false-positive cases,
whereas screening is instead recommended for sympto-
matic persons. In fact, early diagnosis is extremely impor-
tant, given that there exists non-pharmacological and, to
a lesser extent, pharmacological treatment capable of
decreasing the severity of symptoms, retarding disease
progression, and strengthening the residual cognitive abil-
ities when neuronal impairment/death is not complete
[6-11]. Furthermore, managing persons with dementia
and, in particular, the progressive worsening of the disease
entails implementing measures in the family environ-
ment and in the patient's general environment.
General practitioners (GP) could play a key role in detect-
ing persons with symptoms that are suggestive of demen-
tia (e.g., memory deficit and/or alterations in other
cognitive processes). However, many of the neuropsycho-
logical scales and tests for predicting the onset of cognitive
impairment are of limited use for GPs because of the time
and complex training required to administer them [12-
18].
The Mini-Mental State Examination (MMSE) is a widely
used tool for assessing cognitive mental status which can
be administered in less than 10 minutes by following sim-
ple instructions [19-23]. Though it cannot be used for
making formal diagnoses [22], the MMSE has been used
as a first step in detecting cognitive impairment [23-25].
However, few studies have evaluated its accuracy when
used by GPs [24,25].
The objective of the present study was to determine in an
actual public-health setting whether GPs can accurately
detect a cognitive deficit using the MMSE in patients with
suspected cognitive impairment. To this end, we com-
pared the results of the MMSE applied by GPs to those of
the MMSE applied by specialized neuropsychologists.
Methods
The study was conducted as part of a the project "A Model
for Estimating the Occurrence of Alzheimer's Disease for
Creating a Regional Registry and Evaluating Healthcare
Needs", conducted in Rome in 2004–2005 and financed
by the Italian Ministry of Health. The project was per-
formed in compliance with the Declaration of Helsinki
[26] and was approved by the ethics committee of the
"Fatebenefratelli Hospital" (Rome) in February 2004.
Four specialized outpatient centres for dementia partici-
pated in the Project (referred to as "Unità Valutativa Alzhe-
imer", UVA; Alzheimer's Evaluation Units) [27]. The
objectives of the project were: 1) to define criteria for iden-
tifying persons with dementia in the general population;
2) to estimate the incidence and prevalence of dementia;
3) to construct an index of severity of dementia; 4) to
identify neuropsychological, behavioural, and neuro-
physiological predictors of disease progression; 5) to
quantify the resources used in relation to the disease; and
6) to provide useful information for the planning and
development of an integrated model of service provision
based on the network of available services.
In 2004–2005, we contacted the heads of the four Health
Districts in which the above-mentioned UVAs were
located, asking them to recruit GPs who had a private
practice in their Health District. Eighty GPs volunteered to
attend a meeting in which the study was presented; at this
meeting, the GPs were first asked to participate in a course
on dementia, particularly AD, with the aim of updating
their knowledge on diagnostic criteria and patient man-
agement and to train them in the use of the MMSE,
including the interpretation of the scores (for example,
regarding questions on dates, if the answer was off by one
day, then the GPs were instructed to consider this as a
wrong answer).
Sixty-five GPs participated in the course. Of these, 59
agreed to participate in the MMSE evaluation. The GPs,
based on their patients' records, were first asked to iden-
tify persons over 65 years of age who had already been
diagnosed with any form of dementia and those with
memory or cognitive disturbances that were causing diffi-
culties in daily-living activities (reported by the patient
him/herself or a family member) yet who had not suffered
from pathologies other than dementia that cause cogni-
tive impairment (e.g., Down Syndrome) The GPs were
then asked to administer the MMSE (Italian version [28]),
following the instructions for use, to those who had not
already been diagnosed. All evaluated patients, or rela-
tives, were asked to sign an informed consent form.BMC Family Practice 2008, 9:29 http://www.biomedcentral.com/1471-2296/9/29
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The total score for the MMSE ranges from 0 to 30; scores
> 24 indicate basically no cognitive impairment; scores <
18 indicate severe cognitive impairment [20]. For persons
with a score of 24 or lower (corrected by age and educa-
tional level using the score-adjustment coefficients pro-
posed by Magni et al. [28]), the GPs used a standardized
form to collect, with the help of patients' family members,
demographic data, medical history (including pharmaco-
logical use), and family history of dementia. The GP then
invited the patient to undergo a clinical examination at
the UVA, which was scheduled within six months of the
GP's evaluation. The clinical evaluation at the UVA was
based on a standardized protocol and included cognitive
and familial anamnesis, neurological examination, blood
examination, neuroimaging (i.e., computed tomography
or magnetic resonance), neuropsychological evaluation
(i.e., MMSE, the Mental Deterioration Battery [14], the
Stroop Test [29]), functional evaluation [i.e., Activities of
Daily living (ADL) [30] and Instrumental Activities of
Daily Living (IADL) [31]] and behavioural evaluation
through the Neuropsychiatric Inventory (NPI) [32]. The
diagnosis of any form of dementia was made according to
DSM IV criteria [33]; the diagnosis of AD was made
according to NINCS-ADRDA criteria [34]; that of vascular
dementia according to NINDS-AIREN criteria [35] and
that of frontotemporal dementia according to the Lund
and Manchester criteria [36]. Mixed dementia was defined
as the presence of both AD and vascular dementia. Mild
cognitive impairment (MCI) was diagnosed according to
Petersen et al. and Ritchie & Touchon criteria [37-40].
Statistical analysis
Of the patients with suspected cognitive impairment iden-
tified by the GPs, we excluded from the analysis those
being followed by an UVA and those who in the previous
four years had been prescribed inhibitors of acetylcho-
linesterase (AChE), which are indicative of a diagnosis of
dementia.
The scores of the MMSE administered by the GPs were
compared to those of the MMSE administered by the
UVAs. To examine agreement, the difference between the
scores was plotted against their mean (Bland-Altman
plot) [41]. The level of agreement was measured by the
mean difference and the standard deviation of the differ-
ences. The precision of the estimated limits of the agree-
ment was calculated assuming that differences basically
followed a Normal distribution [41]. To provide a syn-
thetic measurement of interrater agreement, the Kappa
statistic was calculated using weights defined as follows:
weights = 1 - [(i - j)/(k - 1)]2
where i and j indicate the scores provided by the two raters
and k is the maximum number of possible ratings (in this
case 31 because the MMSE varies from 0 to 30). This meas-
ure of agreement is scaled to be 0 when the level of agree-
ment is what would be observed by chance and 1 when
there is perfect agreement.
To evaluate factors associated with the magnitude of the
difference between scores, a linear regression model was
used, considering this difference as a dependent variable
and, as independent variables, age (categorized into three
classes), gender, educational level (categorized into four
classes), and the diagnosis made by the UVA (i.e., AD,
other forms of dementia, MCI, and no cognitive impair-
ment). The estimated standard errors were corrected for
the clustering effect due to potential correlation among
scores for the MMSE performed by the same GP [42].
To quantify the accuracy of the MMSE administered by the
GP and by the UVA in discriminating unconfirmed cogni-
tive impairment from any type of cognitive impairment
(i.e., MCI, AD, and other types of dementia) and from AD,
the ROC curves (AUC) were calculated. Finally, the sensi-
tivity, specificity, the percentage of cases correctly classi-
fied, the positive predictive value (PPV), and the negative
predictive value (NPV) were calculated for each score of
the crude and adjusted MMSE administered by GPs and
UVAs.
Results
The GPs identified 552 individuals, of whom 155 had
been previously diagnosed with dementia. Of the remain-
ing 397 individuals, 28 were not tested; for 15 of these
individuals, testing was not possible (e.g., they were insti-
tutionalized), whereas the remaining 13, though not
tested, were nonetheless sent to the UVA based on evi-
dence of cognitive impairment. Thus the GPs performed
the MMSE on 369 individuals. Of these, 11 were excluded
because the MMSE score exceeded 24, and 41 were
excluded from the comparison because the MMSE was not
performed by the UVA. Thus 317 individuals were
included in the present analysis (82% of the eligible can-
didates).
Most of the 317 patients were women (73.5%); the most
represented age group was that of persons 75–84 years of
age (48.6%); and the largest proportion of participants
had a low educational level (0–5 years of schooling)
(68.1%). After the visit to the UVA, 84 (26.5%) of the
cases with suspected cognitive impairment were not con-
firmed, and 40 (12.6%) were defined as affected by MCI;
AD was the most frequent diagnosis of dementia (n = 95;
30.0%). Among the other types of dementia, there were
56 cases of mixed dementia, 33 cases of vascular demen-
tia, 7 cases of frontotemporal dementia, and 2 undeter-
mined cases. When considering both the cases identified
with this study and those already diagnosed, the esti-BMC Family Practice 2008, 9:29 http://www.biomedcentral.com/1471-2296/9/29
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mated prevalence was 3.5% for dementia (1.8% for AD)
among persons aged 65 years or older who were followed
by the 59 GPs.
The mean crude score of the MMSE was 15.8 when the test
was administered by the GPs [standard deviation (SD):
7.96, median: 18, range: 0–27, interquartile range (IQR):
11–22] and 17.4 when it was administered by the UVA
(SD: 9.06, median:19, range: 0–30, IQR: 12–25). The
median time between the two evaluations was 43 days
(IQR: 17–119), during which deterioration in MMSE
scores could be expected. The adjusted mean score (by
educational level and age) was 16.0 when administered
by the GPs [SD: 7.57, median: 18.5, range: 0.4–24.7, IQR:
12.1–22.0] and 17.7 when administered by the UVAs (SD:
8.74, median: 20.0, range: 0–30, IQR: 12.0–24.8). The
mean and the median differences between paired scores
(both crude and adjusted) were 1.58 (SD: 4.28) and 1
(IQR = -1; 4), respectively. Both the mean and the median
differences were significantly different from zero (p <
0.01, by Student's t and Wilcoxon matched pair test). Fig-
ure 1 shows the difference between the paired measure-
ments against their mean. Around 95% of the differences
were between -10.0 and +6.8; for 29.4% of the partici-
pants, the difference between paired MMSE scores was 5
or more. The Kappa statistic was 0.86.
Table 1 shows the unadjusted and adjusted mean differ-
ences between paired scores obtained from the univariate
and multivariate linear regression models, considering as
independent variables age (categorized into three classes),
gender, educational level (categorized into four classes),
and the diagnosis made by the UVA (i.e., AD, other forms
of dementia, MCI, unconfirmed cognitive impairment).
At the univariate analysis, the mean differences were sim-
ilar for males and females. The mean differences signifi-
cantly varied by age class, with patients aged 65–74 years
old having the largest mean differences, whereas those
aged ≥85 years old had a mean difference very close to
zero. For educational level, those with ≥ 14 years of
schooling had the largest mean difference, although this
was not statistically significant. For the UVA diagnosis,
there was a significant difference among the 4 groups,
with very large differences for those with no cognitive
impairment and those with MCI. At the multivariate anal-
ysis, only the mean differences by type of diagnosis still
varied significantly, showing that the age effect found at
the univariate analysis was mainly attributable to con-
founding due to the type of diagnosis. We also explored
other potential factors that could explain the difference
between the paired MMSE scores. However, the UVA
scores were, on average, higher in each participating UVA
(data not shown). Furthermore, we did not find an asso-
ciation with the time between the two administrations. In
Scatter plot of differences between paired MMSE scores and their average; Rome, Italy, 2005 Figure 1
Scatter plot of differences between paired MMSE scores and their average; Rome, Italy, 2005. The diameter of 
the circle points are proportional to the frequency of the individuals with same difference and same average.BMC Family Practice 2008, 9:29 http://www.biomedcentral.com/1471-2296/9/29
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fact, the mean differences were -2.8 for patients re-tested
at the UVAs within 17 days, -1.0 for those re-tested
between 19 and 42 days, -2.3 for those re-tested between
43 and 118 days, and -0.2 for those re-tested after 118
days.
Figure 2 shows the box-plots of the MMSE scores, accord-
ing to the GPs and UVAs, by type of UVA diagnosis. Over-
all, according to both GPs and UVAs, the scores were
highest for persons with unconfirmed cognitive impair-
ment, intermediate for those with MCI and lower for
those with AD or other types of dementia. For persons
with unconfirmed cognitive impairment or MCI, the
UVAs, on average, gave higher scores than the GPs,
whereas the scores were similar for persons with AD or
other types of dementia. The results were very similar
when adjusting the scores for age and educational level
(data not shown in figure).
Figure 3 shows the graphs of the ROC curves of the crude
MMSE scores according to the GPs and the UVAs, which
illustrate the ability to discriminate unconfirmed cogni-
tive impairment from any type of cognitive impairment
(i.e., MCI, AD, and other types of dementia) (panel A)
and from AD (panel B). In both cases, both the scores
given by the GPs and those by the UVAs were able to dis-
criminate (as shown by the AUC), though the scores given
by the UVAs consistently provided a significantly better
discrimination (p < 0.01). The results were very similar
when adjusting the scores for age and educational level
(data not shown in figure).
Finally, we calculated the sensitivity, the specificity, the
percentage of correct classifications, the PPV, and the NPV
for each crude MMSE score provided by GPs and by UVAs,
which was used as cut-off to evaluate the accuracy in dis-
criminating persons with and without cognitive impair-
ment and with AD from those with unconfirmed
cognitive impairment. Table 2 shows the results for cut-off
values between 16 and 26. Regarding the cut-off value to
better discriminate between persons with and without
cognitive impairment, the value of 21 provided the high-
est percentage (i.e, 79.5%) of persons correctly classified
when using the MMSE scores given by the GPs; when con-
sidering the MMSE scores given by the UVAs, the value
that provided the highest percentage of persons correctly
classified was 26 (i.e., 85.5%). Regarding the cut-off value
to better discriminate persons with AD from those with
no cognitive impairment, there was no single cut-off value
for MMSE scores given by GPs. In fact, both the values 18
and 21 provided the highest percentage of persons cor-
rectly classified (i.e., 81.6%). The better cut-off value of
Table 1: Crude and adjusted mean differences of paired MMSE scores obtained by GPs and UVAs for several patient characteristics; 
Rome, Italy, 2005
Unadjusted mean difference SE p-value Adjusted mean difference SE p-value
Gender 0.98 0.43
Female -1.58 0.43 -1.72 0.37
Male -1.60 0.54 -1.21 0.49
Age (in years) 0.02 0.11
65–74 -2.19 0.51 -1.41 0.44
75–84 -2.09 0.43 -1.97 0.39
≥ 85 -0.18 0.57 -1.05 0.55
Educational level (years of schooling) 0.58 0.58
0–5 -1.49 0.45 -1.66 0.33
6–8 -1.56 0.57 -1.09 0.58
9–13 -1.45 0.63 -1.20 0.55
≥ 14 -2.95 0.96 -2.56 1.31
Diagnosis made by UVA < 0.01 < 0.01
Unconfirmed cognitive impairment -4.00 0.44 -3.92 0.54
Mild cognitive impairment -3.22 0.58 -3.25 0.59
Alzheimer's disease -0.17 0.58 -0.16 0.53
Other types of dementia -0.20 0.46 -0.29 0.48
Overall -1.58 0.37
Note: Negative values in the mean differences indicate that the GPs provided higher scores than the UVAs. Adjusted mean differences are 
calculated from a multiple regression linear model, in which the independent covariates were all of the variables reported in the table. Standard 
errors of the estimated parameters of the model are corrected for clustering among patients evaluated by the same GP. P-values are adjusted 
Wald-tests evaluating the probability of having obtained these estimates under the null hypothesis that they were equal to zero (i.e., no difference 
among levels).BMC Family Practice 2008, 9:29 http://www.biomedcentral.com/1471-2296/9/29
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the MMSE scores given by the UVAs was 21 (88.8% cor-
rectly classified).
Discussion
The individuals with suspected cognitive impairment
identified by GPs and sent to the UVAs had, on average,
an MMSE score of 16, suggesting that a large proportion
of them were in an advanced stage of disease without a
specific diagnosis. Many of them were institutionalized or
at home for other co-morbidities, and this study allowed
them to be referred to specialized centres for dementia.
Although dementia continues to be considered as a taboo
for patients, families, and professionals in many coun-
tries, we observed that only 15 of the 397 individuals
(3.8%) were not tested by GPs. This low percentage is
likely the result of the advice and suggestions provided to
the GPs during training to persuade patients and their
families of the benefits of undergoing a specialized evalu-
ation. It may also be due to the fact that the MMSE is easy
to perform. Although there exist briefer tests (i.e., MIS,
MISplus, MINIcog, GPCOG) which could be more attrac-
tive for use in general practice [43], we chose the MMSE
because the others are not commonly used in Italian
UVAs.
Our results showed that there was good agreement
between the MMSE performed by GPs and that performed
by neuropsycologists in the UVAs, although the scores
obtained by the GPs were, on average, significantly lower.
The overall concordance was good (Kappa statistic =
0.86), confirming the high test-retest reliability reported
in several other studies [28]. Our results are also in agree-
ment with those of a similar study performed in France,
which found that the MMSE scores obtained by GPs were
slightly yet significantly higher than those obtained by
trained neuropsychologists. The concordance between
paired scores in the French study was also similar to that
in our analysis [25].
Age, gender, and educational level were apparently not
associated with the difference between paired scores.
There were significant differences when considering the
diagnosis made by the UVA, specifically, for individuals
with no cognitive impairment and those with MCI; how-
ever, it should be mentioned that the MMSE was not
designed to detect patients with MCI. On average, the
scores of the GPs decreased with increasing severity of
dementia, with the highest median score for individuals
with no cognitive impairment and the lowest median
score for those with AD. A similar yet clearer trend was
observed for the scores of the UVAs. It should be consid-
Box-plots of the MMSE scores obtained by GPs and UVAs, stratified by diagnosis made by UVAs; Rome, Italy 2005 Figure 2
Box-plots of the MMSE scores obtained by GPs and UVAs, stratified by diagnosis made by UVAs; Rome, Italy 
2005.BMC Family Practice 2008, 9:29 http://www.biomedcentral.com/1471-2296/9/29
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ered that the MMSE was always administered first by the
GPs and then by the UVAs (after a median time of 43
days), during which time deterioration in MMSE scores
could be expected; however, the time between assess-
ments was not related to the degree of discrepancy. Other
possible reasons for the difference between MMSE scores
could be related to the site, the assessor and the time of
administration, as well as to the specific items of the
MMSE, yet no data were available to explore these hypoth-
eses. We cannot exclude the possibility that for some
patients with important symptoms, or because specifically
requested by the patient's family, the GPs forced the
MMSE to be 24 or less (i.e., the score needed to warrant a
specialised visit by the UVA).
The scores of the GPs showed good accuracy in discrimi-
nating individuals with no cognitive impairment both
from those with cognitive impairment (AUC = 0.80) and
even more so from those with AD (AUC = 0.88). How-
ever, the scores of the UVAs discriminated significantly
Accuracy of the MMSE scores obtained by GPs and UVAs in discriminating individuals with no cognitive impairment from those  with cognitive impairment (panel A) and from those with Alzheimer's disease (panel B) Figure 3
Accuracy of the MMSE scores obtained by GPs and UVAs in discriminating individuals with no cognitive 
impairment from those with cognitive impairment (panel A) and from those with Alzheimer's disease (panel 
B).BMC Family Practice 2008, 9:29 http://www.biomedcentral.com/1471-2296/9/29
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better than those of the GPs. Of note is the finding that,
although the MMSE score has been shown to be influ-
enced by age and educational level [22], we did not find a
higher accuracy when adjusting the scores based on the
Italian normative sample [28] for either the scores of the
GPs or those of the UVAs. This was probably because of
the relative homogeneity of the study population, which
was characterized by a large percentage of persons with a
low educational level (i.e., 0–5 years of education) and
aged 75–84 years old.
The sensitivity and the specificity of several MMSE cut-off
scores in discriminating individuals with no cognitive
impairment from those with impairment and from those
with AD differed from those reported in a previous study
[24], in which analogous cut-offs showed lower sensitivity
and higher specificity. However, these differences can
probably be attributed to the fact that we did not include
those individuals who were likely to have had no cogni-
tive impairment (i.e, MMSE score of GP > 24), thus
increasing the sensitivity and simultaneously reducing the
specificity. Furthermore, we performed a cross-sectional
evaluation to identify cases with cognitive impairment,
whereas the previous study used the MMSE to predict AD
after two years among persons initially not diagnosed
with AD. We found that a cut-off between 18 and 21 pro-
vided the highest percentage of persons correctly classi-
fied. If the MMSE were to be used as a screening tool by
GPs, a cut-off in this range should be considered.
In our study, all types of dementia other than AD, given
the low numbers, were considered as "other types of
dementia", yet we did not evaluate whether the MMSE
scores of the GPs or the UVAs were capable of discriminat-
ing among the different types in this category. One of the
objectives of our study was to identify persons with
slightly compromised cognitive capabilities. We consid-
ered MCI as an intermediate state between normal aging
and dementia [44] and which has been suggested to be a
predictor of dementia [44,45], although it has been esti-
mated that 11–40% of persons with MCI do not worsen
over time and may revert to normal cognitive abilities
[46]. To this regard, some authors have suggested that a
non-pharmacological approach based on cognitive reha-
Table 2: Sensitivity, specificity, and percentage of correct classification of individuals with and without cognitive impairment and those 
with AD and without cognitive impairment for different cut-off scores of the crude MMSE scores obtained by GPs and by UVAs; Rome, 
Italy, 2005
Crude MMSE obtained by GPs Crude MMSE obtained by UVAs
MMSE cut-off 
score
Sensitivity Specificity % correctly 
classified




individuals with and 
without cognitive 
impairment
16 58.8% 85.7% 65.9% 92.0% 41.1% 53.7% 94.1% 64.4% 96.2% 42.3%
17 63.1% 82.1% 68.1% 90.7% 42.9% 55.8% 91.7% 65.3% 94.9% 42.8%
18 66.5% 77.4% 69.4% 89.1% 44.5% 60.1% 91.7% 68.5% 95.2% 45.3%
19 75.1% 69.1% 73.5% 87.1% 45.5% 64.8% 89.3% 71.3% 94.4% 47.8%
20 83.7% 64.3% 78.6% 86.7% 50.0% 70.8% 88.1% 75.4% 94.3% 52.1%
21 88.8% 53.6% 79.5% 84.2% 58.7% 75.1% 85.7% 77.9% 93.6% 55.4%
22 92.7% 39.3% 78.6% 80.9% 63.4% 79.4% 79.8% 79.5% 91.6% 58.3%
23 95.7% 21.4% 76.0% 77.2% 66.0% 83.3% 77.4% 81.7% 91.1% 62.5%
24 98.7% 4.8% 73.8% 74.2% 64.3% 87.1% 72.6% 83.3% 89.8% 67.0%
25 99.6% 0.0% 73.2% 73.4% 57.1% 91.9% 64.3% 84.5% 87.7% 74.0%
26 100.0% 0.0% 73.5% 73.5% 0.0% 94.9% 59.5% 85.5% 86.7% 80.7%
Classification of 




16 71.6% 90.5% 80.5% 89.5% 73.8% 71.6% 94.1% 82.1% 93.2% 74.5%
17 75.8% 85.7% 80.5% 85.7% 75.8% 73.7% 91.7% 82.1% 90.9% 75.5%
18 81.1% 82.1% 81.6% 83.7% 79.3% 75.8% 91.7% 83.2% 91.1% 77.0%
19 83.2% 77.4% 80.5% 80.6% 80.2% 80.0% 89.3% 84.4% 89.4% 79.8%
20 90.5% 69.1% 80.5% 76.8% 86.6% 88.4% 88.1% 88.3% 89.4% 87.1%
21 96.8% 64.3% 81.6% 75.4% 94.7% 91.6% 85.7% 88.8% 87.9% 90.0%
22 96.8% 53.6% 76.5% 70.2% 93.8% 92.6% 79.8% 86.6% 83.8% 90.5%
23 96.8% 39.3% 69.8% 64.3% 91.7% 94.7% 77.4% 86.6% 82.6% 92.9%
24 97.9% 21.4% 62.0% 58.5% 90.0% 94.7% 72.6% 84.4% 79.7% 92.4%
25 99.0% 4.8% 54.8% 54.0% 80.0% 97.9% 64.3% 82.1% 75.6% 96.4%
26 99.0% 0.0% 52.5% 52.8% 0.0% 97.9% 59.5% 79.9% 73.2% 96.2%
Note: Individuals whose score was equal to or lower than the reported cut-off value were classified as having cognitive impairment in the first section of the table and as 
having AD in the second section of the table.BMC Family Practice 2008, 9:29 http://www.biomedcentral.com/1471-2296/9/29
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bilitation and a correct lifestyle may contribute to prevent-
ing MCI and dementia [47].
The MMSE scores of the GPs for individuals with no cog-
nitive impairment were, on average, slightly higher than
those for individuals with MCI, yet the difference was not
statistically significant (p = 0.1); by contrast, the differ-
ence between the MMSE scores of the UVAs for these two
groups was statistically significant (p < 0.01). This result
seems to suggest that the MMSE, when applied by GPs, is
of limited usefulness in distinguishing persons with MCI
from those with no cognitive impairment. However, we
have to take into account that in this study we included
only those persons with scores ≤ 24 according to the GPs.
One of the strengths of our study is that we evaluated the
reliability and accuracy of the MMSE in a sample of indi-
viduals who were not selected and who were in a true gen-
eral-medicine setting. The major limitation of our study is
that the GPs were asked to identify only those patients
who they suspected to have a cognitive deficit (see selec-
tion criteria in the "Methods" section), and only those
patients who scored 24 or less were evaluated by the
UVAs. Thus we do not know how accurate the MMSE used
by GPs would be in detecting cognitive impairment in
patients not suspected to have a deficit (i.e., not sampled)
or in patients with a suspected deficit yet with a score
greater than 24. With regard to the latter patients, we feel
that it is reasonable to assume that there were very few
missed cases with cognitive impairment, as suggested by
the results shown in Figure 2; furthermore, for patients
who scored more than 24 yet whose symptoms were
extremely serious, it was suggested that the GPs refer them
to the UVA, and no cases of suspected cognitive impair-
ment were confirmed. Another limit of our study is that
the single items of the MMSE were not collected, so that
we were not able to evaluate more in-depth whether or
not disagreement between paired scores was due to spe-
cific aspects of the examination. Moreover, patients with
borderline scores (23 or 24) according to the GPs had a
greater probability of receiving higher UVA scores than
patients with scores far below the cut off, simply because
of measurement error and daily variation. In particular,
we cannot exclude the possibility that some of the GPs
may have assigned a score of 24 to persons who, in their
opinion, based on clinical observation or information
provided by family members, were affected by cognitive
impairment. Another limit that should be taken into
account is that the GPs were not randomly selected and
they underwent a training session, limiting the represent-
ativeness with respect to the general community. Further-
more, the UVAs were not blinded to the GPs' MMSE
scores, because patients were invited to go to the UVA
based on the MMSE score. However, it is unlikely that the
UVAs were conditioned by the score given by the GP.
Finally, in this observational study, those who adminis-
tered the MMSE in the UVAs were not blinded to the cog-
nitive and familial anamnesis, the neurological and blood
examinations, neuroimaging, and the neuropsychologi-
cal, functional and behavioural evaluations. However, in
the UVAs' normal clinical practice, the MMSE is adminis-
tered and scored without taking into account the results of
the other measurements for making the clinical diagnosis.
Thus it is unlikely that this would have biased the results.
Conclusion
In conclusion, our study shows that the MMSE can be
used in a general-medicine setting as a useful tool for
identifying cognitive impairment in individuals with
memory or other cognitive impairment. This could con-
tribute to increasing the early identification of persons
with MCI or dementia and thus to increasing the timeli-
ness of pharmacological and non-pharmacological treat-
ment for delaying progression, as well as possible public-
health measures for reducing the social impact for the
affected individuals and their families.
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